Need for examination of broader range of risks when predicting the effects of new tobacco products

Nicotine and Tobacco Research

Volumn 19, Issue 2, 2017, Pages 266-267

  Glantz, Stanton A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; CITATION ANALYSIS; DEATH; HEALTH HAZARD; HEART DISEASE; HUMAN; LETTER; MALIGNANT NEOPLASM; PREDICTION; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SMOKING; SMOKING CESSATION; STEADY STATE; TIME; TOBACCO; VASCULAR DISEASE; UNITED STATES;

NICOTINE;

NICOTINE; PUBLIC HEALTH; SMOKING; TOBACCO; TOBACCO PRODUCTS; UNITED STATES;

EID: 85026604313     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntw231     Document Type: Letter

References (7)

1. Levy DT, Borland R, Villanti AC, et al. The application of a decision-theoretic model to estimate the public health impact of vaporized nicotine product initiation in the United States [published online ahead of print July 14, 2016]. Nicotine Tob Res. 2017;19(2):149-159
2. Nutt DJ, Phillips LD, Balfour D, et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res. 2014;20(5):218-225
3. Bhatnagar A. Cardiovascular perspective of the promises and perils of e-cigarettes. Circ Res. 2016;118(12):1872-1875
4. US Surgeon General. The Health Consequences of Smoking-50 Years of Progress. Rockville, MD: Office of the Surgeon General; 2014
5. Kalkhoran S, Glantz SA. Modeling the health effects of expanding e-cigarette sales in the United States and United Kingdom: a Monte Carlo analysis. JAMA Intern Med. 2015;175(10):1671-1680
6. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016;4(2):116-128
7. Bennett C, Manuel D. Reporting guidelines for modelling studies. BMC Med Res Methodol. 2012;12:168. doi:10.1186/1471-2288-12-168